Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcium carbonate + colecalciferol is a combination of a calcium supplement and Vitamin D3 (cholecalciferol). In the clinical management of endometriosis, this combination is primarily utilized as an 'add-back therapy' for patients undergoing treatment with gonadotropin-releasing hormone (GnRH) agonists, such as leuprorelin. GnRH agonists induce a hypoestrogenic state to alleviate endometriosis symptoms, which can lead to a significant reduction in bone mineral density. The administration of calcium carbonate provides elemental calcium for bone mineralization, while colecalciferol acts as a Vitamin D receptor agonist to enhance intestinal calcium absorption and maintain calcium homeostasis. This specific therapeutic regimen was evaluated by the University of Cagliari in a Phase 4 clinical trial (NCT02420054) to assess its impact on the quality of life and psychological health of women experiencing induced amenorrhea.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium carbonate + colecalciferol.